Price movement over the last 24 hours
ADMA Biologics Inc vs Allbirds Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Allbirds Inc trades at $3.42 (market cap $30.69M). The key difference: ADMA Biologics Inc is far larger — about 69.4× Allbirds Inc's market cap. Which is the better fit depends on your goals.
| ADMA | BIRD | |
|---|---|---|
Market Cap | $2.13B | $30.69M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $16.99 |
52-Week Low | $7.60 | $2.39 |
Enterprise Value | $2.20B | $49.56M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BIRD (Smartbird) trades at $3.47, down 9.87% today, amid a complete pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with negative cash flows and widening losses, though revenue decline has slowed. Recent news highlights the strategic rebranding and new CEO appointment, driving volatile price action. Analyst consensus remains cautious with 78.57% hold ratings, reflecting uncertainty around the business transformation.
Outlook is highly speculative given the radical business model shift. The AI pivot offers growth potential but carries execution risks amid persistent losses and negative equity. Investors face significant volatility as the company transitions, with success dependent on securing AI infrastructure contracts and achieving profitability.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →